{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T21:40:05Z","timestamp":1763156405249,"version":"3.41.2"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite the growing availability of advanced medical therapies for inflammatory bowel disease (IBD), significant gaps remain in treatment initiation. Targeted education and point-of-care clinical decision support may address this gap and lead to improved patient outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multiphase IBD-focused provider education and decision support program spanning 10 years was developed consisting of (1) symposia-based education (n\u2005=\u20051101 learners; 2014 to 2019), (2) point-of-care education (n\u2005=\u20058547 learners) with clinical decision support tool (CDST) deployment (n\u2005=\u200511 940 users, n\u2005=\u2005954 learners; 2019 to 2023), and (3) data-driven platform optimization (2024). Modifications were made through qualitative learner and user surveys, crowdsourced cases to guide implementation, and quantitative data metrics. A matched prepost methodology for testing was used for learners, and a key outcome measure was impact on mastery defined as correctness and confidence for scenario-based questions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Symposia-based education significantly improved provider knowledge, competence, and confidence for all learning domains except shared decision making and treatment selection. Based on learner data and qualitative provider feedback, a freely accessible web-based platform was launched (IBD CDST; www.CDSTforIBD.com). The platform had significant positive impacts on knowledge, competence, confidence, practice, and clinical decision-making learning domains, including shared decision-making. A greater than 200% increase in mastery was observed because of the educational platform model. The impact was consistent for physicians and advanced practice providers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We have built a freely accessible web-based decision support tool platform for advanced medical therapy selection in IBD that significantly improved provider mastery in decision-making for advanced medical therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae270","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:24:15Z","timestamp":1734161055000},"page":"1917-1925","source":"Crossref","is-referenced-by-count":1,"title":["Provider Education and Clinical Decision Support Tool Improve Proficiency in Advanced Therapies for Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-2321","authenticated-orcid":false,"given":"Parambir S","family":"Dulai","sequence":"first","affiliation":[{"name":"Northwestern University, Division of Gastroenterology and Hepatology , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9148-1147","authenticated-orcid":false,"given":"Elizabeth","family":"Johnson","sequence":"additional","affiliation":[{"name":"RMEI, Medical Education , Voorhees, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenny","family":"Cox","sequence":"additional","affiliation":[{"name":"ArcheMedX , Charlottesville, VA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lobna M","family":"Eldasher","sequence":"additional","affiliation":[{"name":"RMEI, Medical Education , Voorhees, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1462-7950","authenticated-orcid":false,"given":"Nicolette","family":"Theriault","sequence":"additional","affiliation":[{"name":"RMEI, Medical Education , Voorhees, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"issue":"3","key":"2025070803370578000_CIT0001","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1053\/j.gastro.2023.10.033","article-title":"Integrating evidence to guide use of biologics and small molecules for Inflammatory Bowel Diseases","volume":"166","author":"Dulai","year":"2023","journal-title":"Gastroenterology."},{"issue":"2","key":"2025070803370578000_CIT0002","doi-asserted-by":"publisher","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","article-title":"Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn\u2019s disease in the United States","volume":"11","author":"Siegel","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"2025070803370578000_CIT0003","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1053\/j.gastro.2019.05.017","article-title":"The impact of delay between biologic prescription and therapy initiation on clinical outcomes in inflammatory bowel disease patients","volume":"157","author":"Agrawal","year":"2019","journal-title":"Gastroenterology."},{"issue":"5","key":"2025070803370578000_CIT0004","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/apt.15609","article-title":"A clinical decision support tool may help to optimise vedolizumab therapy in Crohn\u2019s disease","volume":"51","author":"Dulai","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2025070803370578000_CIT0005","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1053\/j.gastro.2018.05.039","article-title":"Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn\u2019s disease","volume":"155","author":"Dulai","year":"2018","journal-title":"Gastroenterology."},{"issue":"2","key":"2025070803370578000_CIT0006","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/ecco-jcc\/jjaa153","article-title":"Early intervention with vedolizumab on longer term surgery rates in Crohn\u2019s disease: post hoc analysis of the GEMINI phase 3 and long-term safety programs","volume":"15","author":"Dulai","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"13","key":"2025070803370578000_CIT0007","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.cgh.2020.02.010","article-title":"Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis","volume":"18","author":"Dulai","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2025070803370578000_CIT0008","doi-asserted-by":"publisher","first-page":"otac048","DOI":"10.1093\/crocol\/otac048","article-title":"Probability of response as defined by a clinical decision support tool is associated with lower healthcare resource utilization in vedolizumab-treated patients with Crohn\u2019s disease","volume":"4","author":"Dulai","year":"2022","journal-title":"Crohns Colitis 360."},{"issue":"10","key":"2025070803370578000_CIT0009","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/ibd\/izab310","article-title":"Decision support tool identifies ulcerative colitis patients most likely to achieve remission with vedolizumab vs adalimumab","volume":"28","author":"Dulai","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025070803370578000_CIT0010","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/j.cgh.2021.06.037","article-title":"Clinical decision support tool for Infliximab in Crohn\u2019s disease","volume":"20","author":"Dulai","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2025070803370578000_CIT0011","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/ibd\/izab060","article-title":"Vedolizumab clinical decision support tool predicts efficacy of vedolizumab but not ustekinumab in refractory Crohn\u2019s disease","volume":"28","author":"Alric","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025070803370578000_CIT0012","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/ibd\/izac105","article-title":"Feasibility of a clinical decision support tool for ustekinumab to predict clinical remission and relapse in patients with Crohn\u2019s disease: a multicenter observational study","volume":"29","author":"Park","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025070803370578000_CIT0013","doi-asserted-by":"publisher","first-page":"147","DOI":"10.14309\/ajg.0000000000002498","article-title":"Baseline clinical factors are associated with risk of complications in Crohn\u2019s disease: appraisal of the American Gastroenterological Association clinical care pathway","volume":"119","author":"Santiago","year":"2024","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"2025070803370578000_CIT0014","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/j.gastro.2014.07.022","article-title":"Crohn\u2019s disease evaluation and treatment: clinical decision tool","volume":"147","author":"Sandborn","year":"2014","journal-title":"Gastroenterology."},{"issue":"1","key":"2025070803370578000_CIT0015","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1053\/j.gastro.2015.05.036","article-title":"Ulcerative colitis care pathway","volume":"149","author":"Dassopoulos","year":"2015","journal-title":"Gastroenterology."},{"issue":"9","key":"2025070803370578000_CIT0016","doi-asserted-by":"publisher","first-page":"CD003030","DOI":"10.1002\/14651858.CD003030.pub3","article-title":"Continuing education meetings and workshops: effects on professional practice and healthcare outcomes","volume":"9","author":"Forsetlund","year":"2021","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae270\/60924431\/izae270.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/1917\/60924431\/izae270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/1917\/60924431\/izae270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:37:13Z","timestamp":1751960233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/7\/1917\/7914091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,11,29]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae270","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,11,29]]}}}